The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: N4 Pharma hails "encouraging" siRNA research

Thu, 07th Dec 2023 18:28

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Wentworth Resources PLC - Tanzania-focused natural gas production company - Etablissements Maurel & Prom SA, a Paris-based, energy industry-focused company, says it is moving closer to acquiring Wentworth. Explains that it has signed an agreement with the Tanzania Petroleum Development Corporation, which is structured as a 'call option' and allows Tanzania Petroleum to increase its ownership in the production interest by up to 20%. Wentworth has arranged for the Jersey Court to consider and possibly sanction the scheme at a hearing on December 19. Following this date, M&P will take ownership of Wentworth and acquire its 32% direct and indirect interest in Mnazi Bay. Subsequent to the closing of the Acquisition, M&P expects Tanzania Petroleum this call option, meaning that M&P will hold a 60% ownership in Mnazi Bay, and Tanzania Petroleum will hold 40%. M&P says the joint operating agreement will be changed to reflect these new partnership conditions. Adds that it will fund the acquisition with the GBP63 millio placed in escrow.

----------

N4 Pharma PLC - Derbyshire-based specialist pharmaceutical company focused on a delivery system for oncology, gene therapy and vaccines - Says that its work-to-date on its ongoing in vitro small interfering ribonucleic acid research, or siRNA, is "very encouraging", and shows that Nuvec has "considerable potential" to be able to knockdown two independent pathways leading to "more effective "cancer treatments. Explains that it has been investigating the ability of Nuvec nanoparticles to be loaded with, and deliver at the same time, two different siRNA known to inhibit relevant oncology targets. After confirming dual loading of Nuvec, N4 then tested the effect of BRD4 combined with EGFR and PLK1 combined with EGFR on knockdown and cell viability. Says that when when loaded together there was an interaction which resulted in a reduction in knockdown of EGFR receptor, though the reduction on cell viability was retained. It is now exploring varying the amount of each siRNA loaded on Nuvec, and also looking at how low the dose can be reduced to still achieve a functional cell inhibition endpoint. In terms of strategy moving forwards, says that that the precise combinations of siRNA, both in terms of target and concentration of siRNA, will vary depending in which cell type they are tested in.

----------

Software Circle PLC - Manchester-based printing and software company - Regarding the sale of Works Manchester Ltd, says that Works Manchester has filed a notice of intention to appoint administrators. This follows an earlier announcement in June, when Software said it had not received the first instalment of deferred consideration from Rymack Sign Solutions Ltd to buy Works Manchester. Further, due to reduced confidence of receiving payment of any deferred consideration from Rymack, the carrying value of the GBP2.81 million due under the sale and purchase agreement has been reduced to GBP350,000. Software is in the process of taking steps to recover the sums due, and says it will update the market again in due course. Adds that the Nettl Systems management team have been making arrangements with alternative suppliers so that continuity of supply is in place for products available through the Nettl Systems platform.

----------

Ecofin US Renewables Infrastructure Trust PLC - Investor in US renewable energy assets - Expects its Whirlwind Energy wind asset in in Floydada, Texas to reenergise in mid-December, after moving "significantly closer" to coming back online. Says that AEP, the owner of the Matador and Paducah substations, has now finished testing a new transmission line past Matador to Paducah. Adds that the first payment on its business interruption coverage has now been received and further payments are scheduled to follow, "substantially mitigating lost revenue". Meanwhile, the Ellis Road solar farm in Westminster, Massachusetts is back online, following a rodent infestation. Finally, says that progress continues to be made on a previously announced strategic review. Says there can be no certainty as to the outcome of the review or any asset sale process, nor whether any potential transaction or transactions arising could be successfully completed.

----------

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
24 Mar 2020 15:49

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
25 Feb 2020 11:42

N4 Pharma Annual Loss Narrows Amid Work To Improve Nuvec System

N4 Pharma Annual Loss Narrows Amid Work To Improve Nuvec System

Read more
25 Feb 2020 08:49

N4 Pharma narrows loss as it continues development work

(Sharecast News) - Specialist pharmaceutical company N4 Pharma reported a smaller operating loss for 2019 on Tuesday, at ?0.95m, compared to ?1.42m in the prior year.

Read more
11 Feb 2020 14:19

N4 Pharma shares rise on partnership with Nanomerics

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has signed a 14-month research collaboration with Nanomerics to produce and test two candidate formulations using its 'Nuvec' delivery system, it announced on Tuesday.

Read more
11 Feb 2020 11:37

N4 Pharma Signs Research Collaboration Agreement With Nanomerics

N4 Pharma Signs Research Collaboration Agreement With Nanomerics

Read more
18 Sep 2019 12:04

N4 Pharma Interim Loss Widens After Non-Repeat Of Grant, Disposal Gain

(Alliance News) - N4 Pharma PLC on Wednesday said its loss widened slightly in the first half of the year, owing to grant income and a gain on an investment sale the year before which did not in a

Read more
20 Aug 2019 11:49

N4 Pharma Repeats Study And Finds Nuvec Successful At "Certain Doses"

(Alliance News) - N4 Pharma PLC on Tuesday said it has repeated the in-vivo study of Nuvec and shown it does work "when using multiple injections at certain doses".Shares in N4 at

Read more
19 Jun 2019 13:38

N4 Pharma To Start Experiments On Nuvec; Results Due In Two Months

(Alliance News) - N4 Pharma PLC on Wednesday said it will begin experiments on its Nuvec system on Friday this week with results due in around two months.Shares in N4 were up 20% at 4.30 in

Read more
12 Jun 2019 16:04

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 13 JuneTescoWM Morrison SupermarketsSirius MineralsJust Jack 14 Evans 17 18

Read more
21 May 2019 13:25

N4 Pharma Appoints John Chiplin as Non-Executive Chairman

LONDON (Alliance News) - N4 Pharma PLC on Tuesday said it appointed John Chiplin as non-executive chair of the company with immediate effect.Furthermore, the pharmaceutical firm appointed a

Read more
14 May 2019 12:09

N4 Pharma Loss Narrowed By Cost; Will Explore Assets Outside Nuvec

LONDON (Alliance News) - N4 Pharma PLC on Tuesday reported a narrowed loss for 2018 on lower costs and said it is exploring new opportunities while continuing work on core Nuvec drug delivery in -

Read more
15 Apr 2019 15:33

N4 Pharma reassures shareholders over future of 'Nuvec'

(Sharecast News) - Specialist pharmaceutical company N4 Pharma updated the market on the development of 'Nuvec' on Monday, following the disclosure of inconsistencies in the efficacy of Nuvec between various in vitro and in vivo studies.

Read more
15 Apr 2019 15:20

N4 Pharma Finds Issues With In Vivo Nuvec Testing And Plans Repeat

LONDON (Alliance News) - N4 Pharma PLC on Monday said it has become aware of a number of issues with the in vivo studies of its Nuvec delivery system.On Tuesday last week, N4 announced of a

Read more
9 Apr 2019 11:27

N4 Pharma Shares Sink As Nuvec Fails To Produce Response In-Vivo

LONDON (Alliance News) - N4 Pharma PLC on Tuesday said early in-vivo tests of its Nuvec delivery system did not match positive results from in-vitro tests, causing shares to slump.Shares in

Read more
8 Feb 2019 13:18

N4 Pharma Raises GBP1.1 Million In Share Placing To Fund Nuvec System (ALLISS)

LONDON (Alliance News) - N4 Pharma PLC on Firday said it raised GBP1.1 million in a placing of 10.5 million shares at 10 pence each.N4 Pharma shares were trading down 18% at 10.10p each on

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.